UNICEF signs supply agreement with Pfizer for oral COVID-19 treatment

22 March 2022

NEW YORK/COPENHAGEN, 22 March 2022 – UNICEF has signed a supply agreement with Pfizer for the procurement of up to 4 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir (PAXLOVID™) in 2022.

UNICEF procurement of nirmatrelvir/ritonavir (PAXLOVID™) is dependent on country demand, clinical recommendations and necessary approvals.

In December 2021, the US Food and Drug Administration issued an Emergency Use Authorization for the use of nirmatrelvir/ritonavir (PAXLOVID™) for the treatment of mild to moderate cases of COVID-19. Nirmatrelvir/ritonavir (PAXLOVID™) is currently under assessment by the World Health Organization (WHO).

This agreement will help ensure that low- and middle-income countries (LMICs) have timely access to this novel COVID-19 therapeutic. Supply will be made available for procurement and delivery to 95 LMICs, which includes some upper-middle income countries. UNICEF will work closely with WHO and Access to COVID-19 Tools Accelerator (ACT-A) partners such as The Global Fund and Unitaid to ensure equitable access to nirmatrelvir/ritonavir (PAXLOVID™).

UNICEF continues to work with ACT-A partners and industry to facilitate equitable access to COVID-19 therapeutics.


Media contacts

Stephanie Brickman
UNICEF Copenhagen
Tel: +45 408 74876
Tess Ingram
Tel: +1 934 867 7867


UNICEF works in some of the world’s toughest places, to reach the world’s most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone.

Follow UNICEF on TwitterFacebookInstagram and YouTube